In a report published in The Lancet Infectious Diseases (Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomized, double-blind, placebo-controlled, phase 1 and 2 trials) a team led by investigators at the Malaria Research and Training Center (MRTC), Bamako, Mali; the Laboratory of Malaria Immunology and Vaccinology (LMIV), National Institute of Allergy and Infectious Diseases, National Institutes of Health; and Sanaria Inc. describes the durable protective efficacy against malaria shown by Sanaria® PfSPZ Vaccine when administered to women prior to pregnancy.
The impact of AI and ChatGPT on health data – Pharmaceutical Technology
In the healthcare industry, AI is unlocking new possibilities and solving grand healthcare challenges by improving care outcomes, life science innovation, and patient experience in
July 18, 2023